BioVentrix, a medical device firm developing minimally invasive treatments for heart failure, filed on Thursday with the SEC to raise up to $17 million in an initial public offering.
BioVentrix is a medical device company developing and commercializing devices to treat heart failure with reduced ejection fraction (HFrEF). Its lead product, the Revivent System, is designed to restore left ventricular function in HFrEF patients with anterior wall scarring from prior myocardial infarction. The device uses titanium anchors connected by PEEK tethers to plicate scarred, non-functional myocardium and reduce left ventricular volume through a minimally invasive mini-thoracotomy procedure. The procedure is performed on a beating heart and is intended to provide a less invasive alternative to traditional open-heart surgical approaches such as ventricular assist device implantation or heart transplantation. BioVentrix previously generated revenue from the sale of its Revivent TC? TransCatheter Ventricular Enhancement System, which is stopped selling in 2023 to preserve capital.
The Mansfield, MA-based company was founded in 2003 and plans to list on the Nasdaq under the symbol BVXX. BioVentrix filed confidentially on August 5, 2025. The Benchmark Company is the sole bookrunner on the deal. No pricing terms were disclosed.
